← Back to Clinical Trials
Recruiting NCT07350954

NCT07350954 Acceptability and Feasibility of a Brief Paranoia Intervention.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07350954
Status Recruiting
Phase
Sponsor Lucy Jonas
Condition Paranoia
Study Type INTERVENTIONAL
Enrollment 8 participants
Start Date 2025-10-24
Primary Completion 2026-04

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
TRUST

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 8 participants in total. It began in 2025-10-24 with a primary completion date of 2026-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this feasibility and acceptability trial is to test whether a new brief talking therapy can be successfully provided to and is suitable for adolescents (16-18) who are seeking help from Child and Adolescent Mental Health Services (CAMHS). The main research question for the current study is: Is it feasible and acceptable to offer a brief values-based (helping young people identify what matters most to them) and imagery (using imagination to visualise positive experiences) intervention for adolescents experiencing paranoia in CAMHS? It also aims to identify preliminary clinical outcomes, particularly changes in paranoia severity as measured by the Revised Green et al., Paranoid Thoughts Scale (R-GPTS). Participants will complete an eligibility assessment and those eligible will be offered a six-session intervention. Assessment measures will be completed before, during and after the intervention.

Eligibility Criteria

Inclusion Criteria: * Aged 16-18 * Seeking help from a Child and Adolescent Mental Health Service (CAMHS) * A score ≥ 11 on the R-GPTS (Scale B) * Sufficient understanding of English * Capacity to consent, as assessed during the initial interview * Wanting support with paranoia * Low- moderate mental health risks (emotional difficulties that impact functioning, but no immediate risk to safety e.g., no suicidal intent). Exclusion Criteria: * Severe comorbid diagnoses apparent at the initial assessment (e.g., a primary alcohol or substance dependence issue measured using standardised assessments) * The presence of a developmental disability or cognitive impairment that would interfere with participation. * Concurrent participation in another psychological therapy * High levels of current risk (e.g., significant and immediate concerns about the young person's safety, such as suicidal intent).

Contact & Investigator

Central Contact

Jessica Kingston, DClinPsy PhD

✉ jessica.kingston@rhul.ac.uk

📞 +44 1784 414105

Frequently Asked Questions

Who can join the NCT07350954 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, up to 18 Years, studying Paranoia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07350954 currently recruiting?

Yes, NCT07350954 is actively recruiting participants. Contact the research team at jessica.kingston@rhul.ac.uk for enrollment information.

Where is the NCT07350954 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT07350954 clinical trial?

NCT07350954 is sponsored by Lucy Jonas. The trial plans to enroll 8 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology